Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CYTK Catalyst Timeline
Dated clinical, regulatory and corporate events for Cytokinetics, Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cytokinetics, Incorporated
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How CYTK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-16 | MYQORZO (aficamten) | PDUFA Date Approved | PDUFA |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| MYQORZO |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CK-4021586 Small MoleculesNCT06793371 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | RECRUITING | 60 | Sep 1, 2026 | ||||||
| Aficamten Small MoleculesNCT06081894 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Phase 3 | ACTIVE NOT_RECRUITING | 500 | Nov 1, 2026 | ||||||
| Aficamten Small MoleculesMarketedNCT06412666 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Approved | ACTIVE NOT_RECRUITING | 65 | Jan 1, 2030 | ||||||
| Aficamten Small MoleculesMarketedNCT04848506 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | Approved | ENROLLING BY_INVITATION | 900 | Mar 1, 2029 | ||||||
| Omecamtiv mecarbil Small MoleculesNCT01380223 | Heart Failure | Phase 3 | COMPLETED | 10,705 | Apr 1, 2006 | ||||||
| Omecamtiv mecarbil Small MoleculesCompletedNCT02695420 | Heart Failure With Reduced Ejection Fraction | Phase 3 | COMPLETED | 357 | May 8, 2017 | ||||||
| CK-1827452 Small MoleculesCompletedNCT00941681 | Heart Failure | Phase 2 | COMPLETED | 174 | Oct 1, 2009 | ||||||
| Omecamtiv mecarbil Small MoleculesCompletedNCT04175808 | QT Intervals Changes | Phase 1 | COMPLETED | 70 | Mar 4, 2020 | ||||||
| Reldesemtiv Small MoleculesCompletedNCT03160898 | Amyotrophic Lateral Sclerosis | Phase 2 | COMPLETED | 458 | Mar 7, 2019 | ||||||
| Aficamten Small MoleculesMarketedNCT05767346 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Approved | COMPLETED | 457 | Mar 28, 2025 | ||||||
| CK-3773274 Small MoleculesMarketedNCT04219826 | Hypertrophic Cardiomyopathy (HCM) | Approved | COMPLETED | 96 | Feb 28, 2023 | ||||||
| CK-3773274- Granules in Small MoleculesMarketedNCT03767855 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Approved | COMPLETED | 114 | Jan 3, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every CYTK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| aficamten | hypertrophic cardiomyopathy | 2026-11-09 | LVMI reduction: statistically significant (p<0.001); KCCQ OSS improvement: 4.0-point greater improvement; improvement rate: 33.7% vs. 22.5%; deterioration rate: 7.4% vs. 13.3%Read More | Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PARSHALL B LYNNEDirector | Sell | -2,445 8,339 held | $54.17 | 11/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CYTK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 3.8 % (72.7 %) | 425.95 M | 5.00 M | 50% ( 1.67 M) |
Ownership Trends
CYTK Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CYTK ranks across every disease it competes in
CYTK News
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
Cytokinetics announced that the FDA approved an update to MYQORZO's prescribing information, incorporating data from the Phase 3 MAPLE-HCM trial. This trial demonstrated that MYQORZO significantly outperformed the beta-blocker metoprolol in improving exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy. MYQORZO is now the only cardiac myosin inhibitor with comparative effectiveness data in its U.S. label.
Read more →MYQORZO® (aficamten) Receives ASMR III Rating from the HAS (French National Authority for Health) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy in Adults
Cytokinetics announced that MYQORZO® (aficamten) received an ASMR III rating from the French HAS for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. This rating reflects the drug's significant medical benefit and is based on positive results from Phase 3 trials. The decision aims to enhance patient access to this treatment in France.
Read more →Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
Cytokinetics presented new data on aficamten at the HCMS Scientific Sessions 2026. The findings indicate significant improvements in cardiac structure and patient-reported health status in hypertrophic cardiomyopathy patients. Notably, aficamten demonstrated favorable cardiac remodeling and a strong safety profile, with no serious adverse events related to heart failure.
Read more →Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported strong Q3 2026 results with $44.5 million in net revenue from MYQORZO. The company plans to submit a Supplemental NDA for aficamten in non-obstructive HCM by Q4 2026. Positive results from the ACACIA-HCM trial support its potential approval. However, the company reported a net loss of $190.1 million for the quarter.
Read more →Cytokinetics to Participate in November Investor Conferences
Cytokinetics announced participation in several investor conferences throughout November 2026. Key events include fireside chats at the Stifel, UBS, Jefferies, and Evercore conferences. The company continues to advance its drug pipeline, including the planned submission of a Supplemental New Drug Application for aficamten in Q4 2026.
Read more →Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
Cytokinetics will present three studies at the HCMS Scientific Sessions on November 6, 2026. Two of the presentations will focus on Aficamten's effects on non-obstructive hypertrophic cardiomyopathy. The company also plans to submit a Supplemental New Drug Application for Aficamten following positive trial results.
Read more →Cytokinetics to Announce Third Quarter Results on November 4, 2026
Cytokinetics will announce its third quarter results on November 4, 2026, at 4:00 PM ET. A conference call will follow at 4:30 PM ET to discuss the financial results and business updates. The company is advancing its pipeline, including aficamten, which has shown positive results in a Phase 3 trial.
Read more →Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics announced the grant of stock options and restricted stock units to 29 new employees as an inducement for employment. The RSUs will vest over three years, while the stock options have a four-year vesting schedule. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to expanding its workforce.
Read more →Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has received Health Canada approval for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adults. This marks the fifth regulatory approval for MYQORZO within a year, following approvals in the U.S., China, and Europe. The approval is based on positive results from the pivotal Phase 3 SEQUOIA-HCM trial, demonstrating significant improvements in exercise capacity and symptoms. MYQORZO is a well-tolerated treatment option, although it comes with a risk of heart failure due to its effects on left ventricular ejection fraction.
Read more →Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Cytokinetics presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting 2026, highlighting the efficacy and safety of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The analyses showed significant improvements in exercise performance and treatment effects. The company plans to submit a supplemental New Drug Application to the FDA this quarter.
Read more →Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics has announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026, including two Late Breaking Clinical Research presentations. These presentations will focus on the efficacy of Aficamten in treating non-obstructive hypertrophic cardiomyopathy. The meeting will take place in Phoenix, AZ from October 9 to 12, 2026. Cytokinetics continues to advance its pipeline of cardiac treatments.
Read more →Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has launched the ASPEN-HCM study to evaluate MYQORZO (aficamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy. This multicenter, observational study aims to generate real-world evidence on the safety and effectiveness of MYQORZO over 12 to 36 months. The study will assess various clinical outcomes and healthcare resource utilization.
Read more →Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics has announced the ninth annual Communications Grant Program aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy and heart failure. The program will provide grants to enhance communication efforts and community engagement. Applications are open until October 2, 2026, with recipients announced in January 2027.
Read more →Cytokinetics to Participate in September Investor Conferences
Cytokinetics, Inc. announced its participation in several investor conferences in September 2026, including the Citi BioPharma Conference and the Morgan Stanley Global Healthcare Conference. The management team will engage in fireside chats to discuss the company's advancements in cardiac muscle therapies. Cytokinetics is also preparing to submit a Supplemental New Drug Application for aficamten following positive Phase 3 trial results.
Read more →Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics presented additional results from the ACACIA-HCM and MAPLE-HCM trials at the ESC Congress 2026. The findings indicate that aficamten significantly improves cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy (HCM) and outperforms metoprolol in obstructive HCM. These results expand the evidence supporting aficamten's potential use across various HCM patient populations.
Read more →Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Cytokinetics announced positive results from the ACACIA-HCM trial, the first Phase 3 study to show significant improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met its dual primary endpoints, leading the company to plan a supplemental New Drug Application to the FDA. The results were presented at the ESC Congress 2026 and published in The New England Journal of Medicine.
Read more →Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics has announced its participation in the European Society of Cardiology Congress 2026, featuring a Hot Line presentation on the ACACIA-HCM trial's positive results for aficamten in non-obstructive hypertrophic cardiomyopathy. The company will also host an investor event to discuss these findings. Presentations will take place from August 28-31 in Munich, Germany.
Read more →Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported a net product revenue of $25 million for MYQORZO in Q2 2026, indicating strong commercial momentum. The company plans to submit a Supplemental NDA for aficamten in non-obstructive HCM by Q4 2026, following positive results from the ACACIA-HCM trial. Additionally, Cytokinetics is expanding its market presence internationally, with launches in Germany and approvals in the UK.
Read more →